Curaleaf Closes Buyout of Remaining 45% Stake in Germany’s Four 20 Pharma

Curaleaf Holdings(CURA ) disclosed in an April 30 press release issued via Cision Canadian Newswire that it has completed the buyout of the remaining 45% stake in Four 20 Pharma GmbH that it did not previously own. The Paderborn-based, EU-GMP and GDP-licensed medical cannabis producer and distributor is now a wholly owned subsidiary of Curaleaf as of closing. Financial terms for the 45% stake were not disclosed.

The April 30 close completes a path that began with Curaleaf’s August 2022 announcement of an agreement covering a 55% majority interest in Four 20 Pharma. That majority transaction closed on September 16, 2022, per a subsequent Curaleaf disclosure filed with the U.S. Securities and Exchange Commission. The original 55% stake was reported in trade press at the time at approximately €19.7 million; Curaleaf’s April 30 release does not provide a comparable figure for the residual 45% interest, nor a total enterprise value implied by the combined 2022 and 2026 transactions.

A phased structure executed on the longer end of its window

The deal structure — majority stake first, full ownership several years later — is not unusual for foreign acquisitions of German medical cannabis operators, where management retention and continuity of EU-GMP and GDP licensing are practical operating considerations. Curaleaf framed the 2022 transaction at the time as a phased acquisition path with management retention and a path to full ownership; the April 30 release confirms full ownership executed roughly three and a half years after the September 2022 closing of the original 55% interest.

The release positions Four 20 Pharma’s German distribution network — serving pharmacies, nursing homes, and research institutions — as a channel for an international medical cannabis supply chain sourced from Curaleaf cultivation assets in Portugal and Canada. Curaleaf describes Four 20 Pharma as employing 110 people and operating the 420NATURAL brand, launched in 2020.

The April 30 release does not disclose Four 20 Pharma’s revenue contribution to Curaleaf’s consolidated results to date, nor projected revenue under full ownership. The company’s annual information form filed on SEDAR+ on February 26, 2026, referenced in the release for risk-factor language, predates the closing. Granular German segment figures attributable to the full acquisition will appear, if at all, in subsequent quarterly MD&A and a material change report yet to be filed.

Management positioning vs. what is in the release

Curaleaf chairman and CEO Boris Jordan said in the release that the closing reinforces the company’s “commitment to Europe.” Torsten Greif, co-founder and managing director of Four 20 Pharma, said joining Curaleaf “as a fully integrated subsidiary marks an exciting new chapter.” Both statements are positioning from the principals to the transaction. They do not address post-closing operating arrangements, retention terms, or earn-out structures; none of those items are disclosed in the release.

Curaleaf says it has already extended the Four 20 brand into the United Kingdom and Poland and intends to use the German operation’s compliance and production blueprint as a template for further international expansion. That language is forward strategy, not disclosed result. Whether the German blueprint translates to UK and Polish regulatory contexts — both of which differ materially from Germany’s post-KCanG prescribing framework — is an operating question the release does not address. Curaleaf’s broader approach to international medical cannabis has been described in a recent MyCannabis interview with the company’s SVP of innovation and technical manufacturing.

Within Europe’s broader consolidation cycle, but contracted earlier

The closing lands inside an active European consolidation window for North American cannabis companies. Aurora Cannabis announced a C$26.5 million acquisition of Safari Flower Company (ACB ) in mid-April. Organigram Global (OGI ) closed its acquisition of Berlin-based Sanity Group earlier in the month. The pattern reflects a broader North American licensed-producer pivot toward Europe as US cannabis-market visibility has shifted under federal rescheduling.

The Four 20 Pharma transaction does not fit cleanly inside that 2026 consolidation narrative. It was contracted in 2022, before US Schedule III rescheduling became a credible near-term scenario, and its April 30 closing executes a previously committed structure rather than initiating a new one. Reading the closing as a 2026 European bet — rather than as the completion of a 2022 European bet by one of North America’s largest cannabis operators — confuses the deal-status timeline that Curaleaf’s own disclosures lay out.

What changes from here

Four 20 Pharma is now consolidated at 100%, not 55%. Minority-interest line items associated with Four 20 Pharma in Curaleaf’s prior consolidated financial statements will collapse on subsequent filings; the German subsidiary’s revenue, cost of sales, and operating margin will flow fully to Curaleaf shareholders, subject to inter-company tax and transfer-pricing arrangements that the release does not detail.

Whether the full consolidation produces the supply-chain efficiencies and patient-access expansion that management cited in the release will be visible only in subsequent SEDAR+ disclosures — the next quarterly MD&A covering the period of the closing, and any material change report Curaleaf files in connection with the transaction. Until then, the disclosure record is what was confirmed on April 30: the closing itself, the absence of disclosed financial terms for the 45% stake, and the company’s stated intent to use the German operation as a template for expansion that has not yet been quantified.